- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Dechra Receives FDA Approval for First U.S. Generic Entrant Antibiotic
Dechra is pleased to announce that it has received approval from the U.S. Food and Drug Administration for a generic antibiotic. The product is expected to be a first generic market entrant in a substantial antibiotic market.
LONDON, September 9, 2016 /PRNewswire/ —
Dechra (LON:DPH) is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) for a generic antibiotic.
The product is expected to be a first generic market entrant in a substantial antibiotic market; it is the first registration Dechra has achieved through Putney’s development pipeline since it acquired the US-based business and clearly demonstrates the capabilities of our specialist pharma team, a key resource to the Group.
Commenting on the approval Dechra’s Chief Executive Officer, Ian Page said:
“We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra‘s position in the US market.“
The Group’s Preliminary results for the year ended 30 June 2016 were released on 5 September 2016. The Annual Report is now available on the Group website.
For more information, please visit: https://www.dechra.com or e-mail: corporate.enquiries@dechra.com .
SOURCE Dechra Pharmaceuticals PLC
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.